STOCK TITAN
  1. Home
  2. Sec-filings
  3. TEVA
  4. [Form 4] TEVA PHARMACEUTICAL INDUSTRIES LTD Insider Trading Activity

TEVA (TEVA) director Tal Zvi Zaks sells 17 shares, retains 73,247

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Tal Zvi Zaks, a director of TEVA PHARMACEUTICAL INDUSTRIES LTD, reported a sale of 17 Ordinary Shares on 2026-08-05 in a sale in open market or private transaction at $34.8655 per share. Following this transaction, the director directly holds 73,247 Ordinary Shares, which may be represented by American Depositary Shares. The Rule 10b5-1 trading-plan checkbox was not selected.

Positive

  • None.

Negative

  • None.
Insider Zaks Tal Zvi
Role Director
Sold 17 shs ($592.71)
Type Security Shares Price Value
Sale Ordinary Shares F1 17 $34.8655 $592.71
Holdings After Transaction: Ordinary Shares — 73,247 shares (Direct)
Footnotes (1)
  1. F1. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
Shares sold 17 Ordinary Shares Non-derivative sale on 2026-08-05
Sale price per share $34.8655 Price per Ordinary Share for 17-share sale
Shares held after transaction 73,247 Ordinary Shares Direct ownership position following the sale
American Depositary Shares financial
"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."
American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.
Ordinary Shares financial
"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."
Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.
open market or private transaction financial
"transaction_code_description: Sale in open market or private transaction"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →

FAQ

What insider transaction did TEVA director Tal Zvi Zaks report?
Tal Zvi Zaks reported a sale of 17 TEVA Ordinary Shares on 2026-08-05 at $34.8655 per share. The transaction was coded as a sale in open market or private transaction and was reported as a direct ownership change.

How many TEVA shares does Tal Zvi Zaks hold after this Form 4 transaction?
After the reported transaction, Tal Zvi Zaks directly holds 73,247 Ordinary Shares of TEVA. These holdings reflect the position following the 17-share sale reported for 2026-08-05 on the Form 4 filing.

At what price were the 17 TEVA shares sold by Tal Zvi Zaks?
The 17 TEVA Ordinary Shares were sold at a price of $34.8655 per share. The transaction is described as a sale in open market or private transaction, with the price reported on a per-share basis.

Were Tal Zvi Zaks’s TEVA share sales under a Rule 10b5-1 trading plan?
The Form 4 indicates the Rule 10b5-1 trading-plan checkbox was not selected. This means the reported 17-share sale on 2026-08-05 was not affirmatively identified as executed under a Rule 10b5-1 trading plan on the form.

How are TEVA Ordinary Shares held by Tal Zvi Zaks represented in the U.S. market?
The filing notes that TEVA Ordinary Shares may be represented by American Depositary Shares, with each ADS currently representing one Ordinary Share. This applies to the 73,247 Ordinary Shares held after the reported transaction.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Zaks Tal Zvi
(Last)(First)(Middle)
C/O TEVA PHARMACEUTICAL INDUSTRIES LTD.
124 DVORA HANEVI'A ST.,
(Street)
TEL AVIV6944020
(City)(State)(Zip)
ISRAEL
(Country)		2. Issuer Name and Ticker or Trading Symbol
TEVA PHARMACEUTICAL INDUSTRIES LTD [ TEVA ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
08/05/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Ordinary Shares(1)08/05/2026S17D$34.865573,247D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
/s/ Dov Bergwerk as attorney-in-fact for Tal Zvi Zaks08/10/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR